SIOUX CITY (KTIV) - The World Health Organization says chronic obstructive pulmonary disease (COPD) is the third leading ...

After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options.

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

A DISEASE that contributed to hundreds of thousands of emergency hospital admissions last winter needs the same urgency and ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Second Phase 3 Clinical Trial Again Shows Dupilumab Lessens Disease in COPD Patients With Type 2 Inflammation May 20, 2024 — Chronic obstructive pulmonary disease patients with type 2 ...

Respiratory disease testing is a critical aspect of diagnosing and managing various conditions that affect the lungs and ...

The bacteria associated with periodontal disease can be aspirated into the lungs, potentially causing or exacerbating ...

Harbour BioMed submits IND application for HBM9378/SKB378 to China NMPA to treat chronic obstructive pulmonary disease: Suzhou, China Monday, November 11, 2024, 17:00 Hrs [IST] Ha ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...